Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting

June 15, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search